Accuracy of Life Tables in Predicting Overall Survival in Candidates for Radiotherapy for Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 1, 2007, Pages 88-94

  Walz, Jochen ^a   Gallina, Andrea ^a   Hutterer, Georg ^a   Perrotte, Paul ^a   Shariat, Shahrokh F ^a   Graefen, Markus ^a   McCormack, Michael ^a   Bénard, Francois ^a   Valiquette, Luc ^a   Saad, Fred ^a   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Comorbidity; Life expectancy; Life tables; Prostate cancer; Radiotherapy

Indexed keywords

DISEASES; MATHEMATICAL MODELS; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS;

COMORBIDITY; LIFE EXPECTANCY; LIFE TABLES; PROSTATE CANCER;

TUMORS;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMORBIDITY; DECISION MAKING; HUMAN; LIFE EXPECTANCY; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; VALIDATION PROCESS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; HUMANS; LIFE EXPECTANCY; LIFE TABLES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; QUEBEC; SURVIVAL ANALYSIS;

EID: 34547838180     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.02.022     Document Type: Article

References (35)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
2. Scardino P. Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3 Suppl. 1 (2005) S29-S33
3. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
4. Ruchlin H.S., and Pellissier J.M. An economic overview of prostate carcinoma. Cancer 92 (2001) 2796-2810
5. Statistics Canada. Complete life table, Quebec, 2000-2002: MALES. Available at: http://www.statcan.ca/english/freepub/84-537.XIE/tables.htm. Accessed December 20, 2006.
6. Arias E. United States life tables, 2003. Natl Vital Stat Rep 54 (2006) 1-40
7. Alibhai S.M., Naglie G., Nam R., et al. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 21 (2003) 3318-3327
8. Alibhai S.M., Krahn M.D., Cohen M.M., et al. Is there age bias in the treatment of localized prostate carcinoma?. Cancer 100 (2004) 72-81
9. Fowler Jr. F.J., McNaughton Collins M., Albertsen P.C., et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283 (2000) 3217-3222
10. Yan Y., Carvalhal G.F., Catalona W.J., et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88 (2000) 1122-1130
11. Cowen M.E., Halasyamani L.K., and Kattan M.W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 175 (2006) 99-103
12. Tewari A., Johnson C.C., Divine G., et al. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171 (2004) 1513-1519
13. Albertsen P.C., Fryback D.G., Storer B.E., et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156 (1996) 127-132
14. Greenfield S., Apolone G., McNeil B.J., et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 31 (1993) 141-154
15. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 41 (1992) 237-248
16. Kaplan M.H., and Feinstein A.R. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27 (1974) 387-404
17. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
18. Hall W.H., Jani A.B., Ryu J.K., et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8 (2005) 22-30
19. D'Hoore W., Sicotte C., and Tilquin C. Risk adjustment in outcome assessment: The Charlson comorbidity index. Methods Inf Med 32 (1993) 382-387
20. Statistics Canada j. Complete life table, Quebec, 1995-1997: MALES. Available at: http://www.statcan.ca/english/freepub/84-537.XIE/1997001/tables.htm. Accessed December 20, 2006.
21. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
22. American Cancer Society. Cancer facts and figures 2006 (2006), American Cancer Society, Atlanta, GA
23. McDavid K., Lee J., Fulton J.P., et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119 (2004) 174-186
24. Bray F., Sankila R., Ferlay J., et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 (2002) 99-166
25. Chow E., Davis L., Panzarella T., et al. Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 61 (2005) 870-873
26. Henderson R., Jones M., and Stare J. Accuracy of point predictions in survival analysis. Stat Med 20 (2001) 3083-3096
27. Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: Preoperative application in prostate cancer. Curr Opin Urol 13 (2003) 111-116
28. Boulos D.L., Groome P.A., Brundage M.D., et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer 106 (2006) 1804-1814
29. Albertsen P.C., Fryback D.G., Storer B.E., et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274 (1995) 626-631
30. Arredondo S.A., Elkin E.P., Marr P.L., et al. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE. Urology 67 (2006) 559-565
31. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005-7012
32. Fowler Jr. J.E., Terrell F.L., and Renfroe D.L. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 156 (1996) 1714-1718
33. Goldner G., Wachter S., Wachter-Gerstner N., et al. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 182 (2006) 537-542
34. Wong Y.N., Mitra N., Hudes G., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683-2693
35. Tewari A., Raman J.D., Chang P., et al. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology 68 (2006) 1268-1274